Abstract
The aerosol form of the bacterium Yersinia pestis causes the pneumonic plague, a virulent and rapidly fatal disease that develops within days post-infection. In the context of a bioterror threat, an ideal anti-plague vaccine should elicit rapid, robust and long-acting protective immunity after a single dose. At present, no plague vaccines are available for use in the USA. One candidate for developing a subunit vaccine is the Yersinia pestis V antigen, a protein that influences the function of the Yersinia outer membrane proteins (Yops) virulence factors and has local anti-inflammatory effects in the host.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
